GSK's older adult RSV vaccine candidate, containing Agenus' QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trialGlobeNewsWire • 10/13/22
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma PatientsBusiness Wire • 10/12/22
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
Here is What to Know Beyond Why Agenus Inc. (AGEN) is a Trending StockZacks Investment Research • 09/30/22
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced MelanomaGlobeNewsWire • 09/12/22
Agenus Inc. (AGEN) CEO Garo Armen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid TumorsGlobeNewsWire • 08/01/22